Achieve Life Sciences Inc ACHV.OQ ACHV.O is expected to show no change in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
LSEG's mean analyst estimate for Achieve Life Sciences Inc is for a loss of 26 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Achieve Life Sciences Inc is $13.00, about 60.7% above its last closing price of $5.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.40 | -0.36 | -0.37 | Missed | -1.6 |
Mar. 31 2025 | -0.38 | -0.36 | -0.37 | Missed | -1.8 |
Dec. 31 2024 | -0.36 | -0.32 | -0.36 | Missed | -12.5 |
Sep. 30 2024 | -0.28 | -0.26 | -0.36 | Missed | -37.7 |
Jun. 30 2024 | -0.23 | -0.23 | -0.25 | Missed | -7.9 |
Mar. 31 2024 | -0.25 | -0.24 | -0.26 | Missed | -6.6 |
Dec. 31 2023 | -0.31 | -0.31 | -0.26 | Beat | 17.3 |
Sep. 30 2023 | -0.37 | -0.38 | -0.34 | Beat | 10.2 |
This summary was machine generated November 4 at 13:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)